Skip to main content

United StatesBreaking News

Grafa

Clearmind Medicine hits primary safety endpoint in Phase I/IIa alcohol use disorder trial

Clearmind Medicine (NASDAQ:CMND), a clinical-stage biopharmaceutical company focused on neuro-therapeutics, announced on Tuesday, April 14, 2026, that its lead oral candidate, CMND-100, successfully met the primary safety and tolerability endpoints in an FDA-approved Phase I/IIa dose-escalation trial.

Read more